Johnson & Johnson (JNJ) is a $376 billion market cap company trading at $140 per share focused on innovative health care products for people around the world for over 130 years. The company shared its plans for it's impressive pipeline and future goals for sustainable growth in May 2017. As JNJ presses forth with its industry-leading business development model by leveraging its core blockbuster products, it is also making key acquisitions. The company's proven track record of commercial capabilities, pharmaceutical sector innovation in unmet needs, and strong position in medical devices makes the company an attractive long-term growth candidate. Strong Bio is recommending a position in JNJ for portfolios looking to protect gains made from emerging speculative stocks, that still seek strong growth potential. Stocks such as JNJ and others that have been recently featured as combined growth and defensive allocations help eliminate volatility and legal quagmire when suitor and managerial manipulation of speculative drug candidates becomes egregious, an unfortunate emerging trend in biotechnology.

READ FULL ARTICLE HERE